留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

双氢青蒿素抗癌药理作用机制的研究进展

周许薇 谭蔚锋 解方园 辛宝 陈俊

周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
引用本文: 周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
Citation: ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003

双氢青蒿素抗癌药理作用机制的研究进展

doi: 10.3969/j.issn.1006-0111.2019.03.003

Research progress on anti-tumor mechanisms of dihydroartemisinin

  • 摘要: 双氢青蒿素是青蒿素的一种重要衍生物,是我国自行研发的抗疟新药。近年来,人们发现双氢青蒿素不但具有抗疟活性,而且具有良好的抗肿瘤效果,被认为是前景良好的抗肿瘤药。因此,综述目前双氢青蒿素抗肿瘤作用发生机制、靶点和通路的研究进展,主要包括癌细胞凋亡、内质网应激、癌细胞生长增殖、侵袭转移、肿瘤多药耐药以及细胞氧化损伤等方面。为抗肿瘤的基础研究、新药物研发以及药物设计提供参考和依据。
  • [1] WONG Y K,XU C,KALESH K A,et al.Artemisinin as an anticancer drug:recent advances in target profiling and mechanisms of action[J].Med Res Rev,2017,37(6):1492-1517.
    [2] 郭宗儒.青蒿素类抗疟药的研制[J].药学学报,2016,51(1):157-164.
    [3] LU J J,MENG L H,SHANKAVARAM U T,et al.Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells[J].Biochem Pharmacol,2010,80(1):22-30.
    [4] LIANG S,SUN K,WANG Y,et al.Role of Cyt-C/caspases-9,3,Bax/Bcl-2 and the FAS death receptor pathway in apoptosis induced by zinc oxide nanoparticles in human aortic endothelial cells and the protective effect by alpha-lipoic acid[J].Chem Biol Interact,2016,258:40-51.
    [5] HE Q,SHI J,SHEN X L,et al.Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells[J].Cancer Biol Ther,2010,9(10):819-824.
    [6] KONG R,JIA G,CHENG Z X,et al.Correction:dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5[J].Plos ONE,2012,7(5):e37222.
    [7] LI Y W,ZHANG W,XU N,et al.Dihydroartemisinin inhibits proliferation of pancreatic cancer JF-305 cells by regulating expression of apoptosis related proteins and production of reactive oxygen species[J].Zhongguo Zhong Yao Za Zhi,2017,42(15):3026-3030.
    [8] ZUO Z J,WANG S T,JIANG L X,et al.Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study[J].Zhongguo Zhong XI Yi Jie He Za Zhi,2014,34(10):1220-1224.
    [9] LU M,SUN L,ZHOU J,et al.Dihydroartemisinin-induced apoptosis is associated with inhibition of sarco/endoplasmic reticulum calcium ATPase activity in colorectal cancer[J].Cell Biochem Biophys,2015,73(1):137-145.
    [10] QIN G,ZHAO C,ZHANG L,et al.Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells[J].Apoptosis,2015,20(8):1072-1086.
    [11] LIAO K,LI J,WANG Z.Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells[J].Int J Clin Exp Pathol,2014,7(12):8684.
    [12] FASANO E,SERINI S,PICCIONI E,et al.DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines[J].Biochim Biophys Acta,2012,1822(11):1762-1772.
    [13] CHEN S S,HU W,WANG Z,et al.p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy[J].Cancer Biol Ther,2015,16(5):770-779.
    [14] CHEN M,CHEN T S,LU Y Y,et al.Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells[J].Pathol Oncol Res,2012,18(4):809-816.
    [15] ZHANG C,SYED T W,LIU R,et al.Role of endoplasmic reticulum stress,autophagy,and inflammation in cardiovascular disease[J].Front Cardiovasc Med,2017,4:29.
    [16] DU X X,LI Y J,WU C L,et al.Initiation of apoptosis,cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin[J].Biomed Pharmac,2013,67(5):417-424.
    [17] MARCINIAK S J,RON D.Endoplasmic reticulum stress signaling in disease[J].Physiol Rev,2006,86(4):1133-1149.
    [18] SCHRÖDER M.Endoplasmic reticulum stress responses[J].Cell Mol Life Sci,2008,65(6):862-894.
    [19] WANG M,KAUFMAN R J.Protein misfolding in the endoplasmic reticulum as a conduit to human disease[J].Nature,2016,529(7586):326-335.
    [20] HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
    [21] INGHAM M,SCHWARTZ G K.Biology of neoplasia:cell-cycle therapeutics come of age[J].J Clin Oncol,2017,35(25):2949-2959.
    [22] MAGENTA D,SANGIOVANNI E,BASILICO N,et al.Inhibition of metalloproteinase-9 secretion and gene expression by artemisinin derivatives[J].Acta Trop,2014,140:77-83.
    [23] LIN R,ZHANG Z,CHEN L,et al.Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells[J].Cancer Lett,2016,381(1):165-175.
    [24] TONG Y,LIU Y,ZHENG H,et al.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling[J].Oncotarget,2016,7(21):31413-31428.
    [25] MI Y,GENG G,ZOU Z,et al.Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells[J].PloS ONE,2015,10(3):e0120426.
    [26] ALASEEM A,ALHAZZANI K,Dondapati P,et al.Matrix metalloproteinases:a challenging paradigm of cancer management[J].Semin Cancer Biol,2017,Epub.
    [27] SHAO Y Y,ZHANG T L,WU L X,et al.AKT Axis,miR-21,and RECK play pivotal roles in dihydroartemisinin killing malignant glioma cells[J].Int J Mol Sci,2017,18(2):350.
    [28] HWANG Y P,YUN H J,KIM H G,et al.Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms[J].Biochem Pharmacol,2010,79(12):1714-1726.
    [29] HU C J,ZHOU L,CAI Y.Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2[J].Cancer Biol Ther,2014,15(3):279-288.
    [30] CHEN J,CHEN X,WANG F,et al.Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway[J].Neurol Sci,2015,36(3):435-440.
    [31] WANG S J,SUN B,CHENG Z X,et al.Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway[J].Cancer Chemother Pharmacol,2011,68(6):1421.
    [32] PILATI P,NITTI D,MOCELLIN S.Cancer resistance to type Ⅱ topoisomerase inhibitors[J].Curr Med Chem,2012,19(23):3900-3906.
    [33] WIJDEVEN R H,PANG B,ASSARAF Y G,et al.Old drugs,novel ways out:Drug resistance toward cytotoxic chemotherapeutics[J].Drug Resist Updat,2016,28:65-81.
    [34] ONTIKATZE T,RUDNER J,HANDRICK R,et al.Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells[J].Front Oncol,2014,4:116.
    [35] CARO J T,MARíN L M,IAZBIK M C,et al.Markers of iron metabolism in retired racing greyhounds with and without osteosarcoma[J].Vet Clin Pathol,2013,42(3):360-363.
    [36] JIA L,SONG Q,ZHOU C,et al.Dihydroartemisinin as a putative STAT3 inhibitor,suppresses the growth of head and neck squamous cell carcinoma by targeting Jak2/STAT3 signaling[J].PloS ONE,2016,11(1):e0147157.
    [37] CAO L,DUANMU W,YIN Y,et al.Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3[J].Pharmazie,2014,69(10):752-758.
  • [1] 方宇昕, 李育, 刘宝姝, 董国强.  线性泛素连接酶复合体与去线性泛素化酶在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(9): 534-539. doi: 10.12206/j.issn.2097-2024.202307045
    [2] 高习清, 卢光照, 鲁莹, 邹豪.  活性氧自由基响应型脂质体在抗肿瘤研究中的应用进展 . 药学实践与服务, 2023, 41(1): 14-17. doi: 10.12206/j.issn.2097-2024.202105086
    [3] 王智聪, 谢彬, 袁星, 徐希科, 柳润辉.  基于网络药理学探讨麝香保心丸治疗动脉粥样硬化作用机制 . 药学实践与服务, 2023, 41(5): 296-301. doi: 10.12206/j.issn.2097-2024.202112001
    [4] 黄晴, 施春燕.  基于网络药理学研究白芍治疗肝纤维化的作用机制 . 药学实践与服务, 2023, 41(8): 485-491. doi: 10.12206/j.issn.2097-2024.202208040
    [5] 谢彬, 袁星, 徐希科, 柳润辉.  中药复方抗动脉粥样硬化作用机制的研究进展 . 药学实践与服务, 2021, 39(4): 295-298, 304. doi: 10.12206/j.issn.1006-0111.202103001
    [6] 丁佳宁, 马进原, 朱全刚.  长链非编码RNA人母系表达基因3在肿瘤发生中作用的研究进展 . 药学实践与服务, 2019, 37(5): 390-393,421. doi: 10.3969/j.issn.1006-0111.2019.05.002
    [7] 陈自强, 张玮, 李玉平, 王晓宇.  纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展 . 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
    [8] 王欢, 马志强, 杨峰.  用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展 . 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
    [9] 赵娜, 高峰, 刘彬, 朴贤美.  苄基四氢异喹啉类生物碱的药理作用及其研究进展 . 药学实践与服务, 2015, 33(4): 313-315,323. doi: 10.3969/j.issn.1006-0111.2015.04.006
    [10] 武善超, 盛春泉, 张万年.  来源于天然产物的抗肿瘤先导结构研究进展 . 药学实践与服务, 2014, 32(5): 337-341,371. doi: 10.3969/j.issn.1006-0111.2014.05.005
    [11] 牛筛龙, 孙富增, 张兴耐.  秦艽总环烯醚萜苷的抗炎作用及其机制 . 药学实践与服务, 2013, 31(3): 198-200. doi: 10.3969/j.issn.1006-0111.2013.03.010
    [12] 赵心彬, 倪敏, 陶霞.  他汀类药物多效药理作用及其机制研究进展 . 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005
    [13] 路明珠, 张治强, 伊佳, 陈万生, 侯忠海, 李铁军.  知母皂苷B-Ⅱ抗抑郁作用及其机制研究 . 药学实践与服务, 2010, 28(4): 283-287.
    [14] 侯雪梅, 崔黎丽, 李国栋, 李卫华.  抗肿瘤药物靶向制剂研究进展 . 药学实践与服务, 2007, (5): 273-275,280.
    [15] 黄宝康, 郑汉臣, 秦路平.  缬草属植物的镇静催眠作用及机制 . 药学实践与服务, 2007, (3): 134-136,142.
    [16] 丁力, 丁家崇, 郭葆玉.  抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
    [17] 庞晓军, 黄军章, 刘国勇, 李香乐.  肿瘤基因治疗研究进展 . 药学实践与服务, 2006, (1): 4-6.
    [18] 王彦, 刁亚英, 姜远英.  ABC转运蛋白与肿瘤多药耐药 . 药学实践与服务, 2003, (1): 28-31.
    [19] 肖文中, 詹利之, 张美义, 林燕芳.  三波长分光光度法测定复方双氢青蒿素片中双氢青蒿素的含量 . 药学实践与服务, 2003, (2): 92-94.
    [20] 范开华, 刘子文, 夏俊.  血卟啉二乙二醇对消化道肿瘤的光动力疗效观察 . 药学实践与服务, 2001, (2): 76-76.
  • 加载中
计量
  • 文章访问数:  4365
  • HTML全文浏览量:  767
  • PDF下载量:  411
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-28
  • 修回日期:  2019-01-25

双氢青蒿素抗癌药理作用机制的研究进展

doi: 10.3969/j.issn.1006-0111.2019.03.003

摘要: 双氢青蒿素是青蒿素的一种重要衍生物,是我国自行研发的抗疟新药。近年来,人们发现双氢青蒿素不但具有抗疟活性,而且具有良好的抗肿瘤效果,被认为是前景良好的抗肿瘤药。因此,综述目前双氢青蒿素抗肿瘤作用发生机制、靶点和通路的研究进展,主要包括癌细胞凋亡、内质网应激、癌细胞生长增殖、侵袭转移、肿瘤多药耐药以及细胞氧化损伤等方面。为抗肿瘤的基础研究、新药物研发以及药物设计提供参考和依据。

English Abstract

周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
引用本文: 周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
Citation: ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
参考文献 (37)

目录

    /

    返回文章
    返回